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Adipose tissue metabolism is closely linked to insulin resistance, and diﬀerential fat distributions are associated with disorders
like hypertension, diabetes, and cardiovascular disease. Adipose tissues vary in their impact on metabolic risk due to diverse gene
expression proﬁles, leading to diﬀerences in lipolysis and in the production and release of adipokines and cytokines, thereby
aﬀecting the function of other tissues. In this paper, the roles of the various adipose tissues in obesity are summarized, with
particular focus on mitochondrial function. In addition, we discuss how a functionally mitochondrial-targeted compound, the
modiﬁed fatty acid tetradecylthioacetic acid (TTA), can inﬂuence mitochondrial function and decrease the size of speciﬁc fat
depots.
1.Introduction
In a modern lifestyle people are chronically exposed to
elevated amounts of lipids and nutrients, potentially leading
to tissue dysfunction and disease [1]. The adipose tissue is
highly involved in the development of metabolic disorders
such as cardiovascular disease (CVD) and type 2 diabetes
mellitus (T2DM). It is the body’s largest storage site for
triglycerides and plays an important role as an endocrine
organ in energy homeostasis [2]. The adipose tissue is
divided into speciﬁc regional depots with diﬀerences in
structural organization, cellular size, and biological function
[3]. The distribution of fat between these depots seems to be
moreimportantthanthetotaladiposetissuemassfortherisk
of developing obesity-associated diseases (Figure 1).
Normally, fat storage in the form of neutral triglycerides
takes place during food intake to be replaced by fat mobi-
lization processes during fasting or situations with elevated
energydemand(Figure 2(A)).Adipocytesproduceanumber
of endocrine hormones that contribute to the regulation
of this mechanism, such as adiponectin and leptin. As
adipocytes play a key metabolic role as a source of fuel, they
are required to respond acutely to changes in the nutritional
levels. As a result they are tightly regulated by both hormonal
(e.g., insulin) and sympathetic (e.g., adrenergic) stimulation
[2].
Metabolic syndrome is a group deﬁnition on several
diseases connected to obesity. Subjects will display elevated
levels of glucose and nonesteriﬁed fatty acids, also called free
fatty acids (FFAs), and show symptoms of one or more aﬄic-
tions amongst which hypertension, hypertriglyceridemia,
diabetes, and obesity are the most usual. Lipotoxitcy and the
accumulation of saturated fat in peripheral tissues are an
important step in the development of metabolic syndrome.
Fatty liver (liver steatosis) is found in a large proportion
of individuals with body mass index (BMI) above 30. Liver
steatosis contributes to insulin resistance and may lead to the
development of nonalcoholic fatty liver diseases (NAFLDs),
including nonalcoholic steatohepatitis (NASH) and cirrhosis
[4].
T2DM is usually linked to obesity and lipid redistribu-
tion to nonadipose organs and tissues and is caused by a
reduced sensitivity to insulin in muscle, liver, and adipose
tissue [1]. During insulin resistance, an increase in insulin2 Journal of Obesity
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Figure 1: (A) The main white adipose tissues (WATs) are abdominal subcutaneous adipose tissue (SAT, (a)), and visceral adipose tissue
(VAT). VAT surrounds the inner organs and can be divided in omental (b), mesenteric (c), retroperitoneal ((d): surrounding the kidney),
gonadal ((e): attached to the uterus and ovaries in females and epididymis and testis in men), and pericardial (f). The omental depot
stars near the stomach and spleen and can expand into the ventral abdomen, while the deeper mesenteric depot is attached in a web-form
to the intestine. The gluteofemoral adipose tissue (g) is the SAT located to the lower-body parts and is measured by hip, thigh, and leg
circumference. WAT can also be found intramuscularly (h). Brown adipose tissue is found above the clavicle ((i): supraclavicular) and in
the subscapular region (j). Although the mentioned subcutaneous and visceral adipose tissues are found in humans, depots (d) and (e) are
mostly studied in rodents. (B) The adipose tissue depots that have been linked to risk of developing obesity-related diseases are indicated in
red. The best-documented link to risk is found for the omental and mesenteric VAT.
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Figure 2: (A) The role of white adipose tissue (WAT) is to store excess dietary fat in the form of triglycerides (TGs) and to release free fatty
acids (FFAs) in times of starvation or energy demand. In addition WAT releases several important factors that regulate energy homeostasis.
Lipolysis takes place in the cytosol and is also dependent on processes in the mitochondria. The resulting FFA can be released to the blood or
directlyusedasanenergysourcebyβ-oxidationinthemitochondria.Inlipogenesis,glycerolandacyl-CoAproducedinthemitochondriaare
used to generate TG for storage in the adipocytes. (B) In brown adipose tissue (BAT) the FFAs are β-oxidized, and the resulting acetyl-CoA
enters the Krebs cycle. The reduction potential is used to form a mitochondrial proton gradient that instead of producing ATP is released by
uncoupling protein 1 (UCP1), a process that generates heat.Journal of Obesity 3
does not lead to a corresponding increased uptake of glucose
in muscle and liver. As a compensatory mechanism insulin
production is increased in pancreatic beta cells. T2DM
occurs when the increased insulin production is no longer
suﬃcient, or when lipid-induced beta cell malfunction takes
place, particularly in genetically predisposed individuals. It
is believed that high levels of circulating FFA and lipotoxic
mechanisms can cause damage on β-cell and nonislet tissues.
CVD includes hypertension, atherosclerosis, heart dis-
ease, vascular disease, and stroke. Several of the high-risk
factors for CVD result directly or indirectly from obesity
and a malfunctioning adipose tissue: dyslipidemia, chronic
inﬂammation, diabetes, and hypertension. Mitochondrial
dysfunction could also contribute to CVD due to their role
as targets and sources of reactive oxygen species (ROS), both
in the formation of vascular lesions and in their involvement
in the development of insulin resistance and T2DM [5].
A well-functioning adipose tissue with capacity to neu-
tralize and store nutritional overload is therefore necessary
to protect the body from peripheral insulin resistance. Two
closely linked processes in adipose tissue are important
for the development of metabolic disease: adipose tissue
inﬂammation and adipose tissue hypertrophy. Adipose tis-
sue inﬂammation due to the recruitment of T-cells and
macrophages has been shown to contribute to insulin
resistance in obese individuals. This inﬂammation leads to
a disturbed adipokine-balance and an uncontrolled release
of free fatty acids and inﬂammatory cytokines [6]. As a
result, lipoprotein metabolism and insulin sensitivity in
o t h e ro r g a n sw i l lb ea ﬀected. During obesity, the adipocyte
size increases (hypertrophy), and they are eventually unable
to store excess lipids even with enhanced adipocyte pro-
liferation (hyperplasia). This redirects fatty acids to the
liver promoting dyslipidemia, characterized by elevated
plasma FFA, triglycerides (TGs), and small dense low-
density lipoprotein (LDL), and the reduction of high-density
lipoproteins (HDLi). In addition large adipocytes are char-
acterized by an increased lipolysis, the breakdown of stored
TG by lipases. This results in FFA and glycerol, which further
increases plasma FFA-levels and upregulates TG synthesis
in the liver [7]. A recent publication demonstrated that
enlarged adipocytes in obese men had a reduced rate of FFA-
delivery to the blood stream, resulting in normal systemic
FFA concentrations. However, after meals the adipose tissue
storage capacity was severely impaired, thus potentially
causing ectopic lipid deposition [8].
How well the adipose tissue functions as a storage
organ for excess energy intake and the distribution of fat
and mitochondria between the diﬀerent adipose depots
may determine the large diﬀerences in health observed
in obese individuals. Here, we will ﬁrst focus on the
importance of mitochondrial function in adipose tissue and
then describe the diﬀerent adipose tissue depots, in rodent
animalmodelsaswellashumans(Figure 1),andtheirimpact
on the development of metabolic diseases. Pharmacological
treatments that speciﬁcally target mitochondria have great
potential in the treatment of obesity-related disorders,
and their diﬀerential eﬀect on adipose depots will be
discussed.
2. Reactive OxygenSpeciesduringObesity
An elevated metabolism during obesity results in increased
production of reactive oxygen species (ROS). ROS damage is
most likely involved in all features of metabolic syndrome.
Increased ROS production is an early event in glucose
intolerance, contributing to pancreatic β-cell dysfunction as
well as liver steatosis. β-cells may be specially susceptible to
ROS-damage due to their relatively low expression of free-
radical-detoxifying enzymes compared to most other cell
types [9].
There are indications that mitochondrial content and
function in adipose tissue might be disrupted in metabolic
disorders. It has been suggested that insulin resistance is
linked to mitochondrial dysfunction [10, 11]. Furthermore,
it is increasingly evident that oxidative capacity and thus
mitochondria are fundamental to avoid the development of
toxicity during excess energy intake. For instance, increase
in mitochondrial ROS is observed in adipose tissue during
obesity [12–14], and in skeletal muscle, the mitochondrial
H2O2 emission is higher using fatty acids as substrates
versus carbohydrate-based substrates [15, 16]. Two models
of insulin resistance, induced by either tumor necrosis factor
α (TNFα) or glucocorticoid treatment, were both shown to
involve increased ROS levels [17]. Also, antioxidants atten-
uating mitochondrial H2O2 emission completely restored
insulin sensitivity in skeletal muscle [16]. These ﬁndings
show that mitochondria play a central role in the physiology
leading to insulin resistance.
Inaddition, theNOXfamilyofNADPHoxidases,located
to the plasma membrane, cytosol and cytosolic membranes,
is a major source of ROS generation. NOX2 is an energy
transporter that catalyses the reduction of oxygen to O
−
2 in
an NADPH-dependent reaction. The involvement of NOX
enzymes in the development of metabolic syndrome has
been reviewed by Krause and coauthors [18, 19]. In low
concentrations, ROS participates in the cell signaling as
secondary messengers [20]. In response to insulin, NOX
will release ROS that activates the distal insulin-signaling
cascade, mobilizing glucose transporters to the surface of
adipocytes. However in higher amounts it will have serious
harmful eﬀects on the cells, including decreased glucose
uptake in adipocytes [21]. Several mouse obesity models
have found an increase in oxidative stress in adipose tissue
associated with overexpression of NADPH oxidase and
repression of antioxidative enzymes such as catalase [13].
Also, mitochondrial proliferation is inhibited by increased
ROS production [22, 23], indicating that ROS can modulate
adipocyte generation.
3. Mitochondria inAdipose Tissue
Well-functioning mitochondria are essential in adipose
tissue. Mature adipocytes require large amounts of ATP
to maintain their activities such as lipolysis, fatty acid
β-oxidation, and fatty acid synthesis. In the organism,
mitochondria produce energy and are central in the fatty
acid metabolism since more than 98% of fatty acids are
oxidized in mitochondria [24]. Recent evidence indicates4 Journal of Obesity
thatareducedmitochondrialfunctionandalteredbiogenesis
play important roles in the etiology of obesity, insulin
resistance,andT2DM[25].Animpairedmetabolicﬂexibility
is the inability of an organism to adapt fuel oxidation to fuel
availability. The ability to switch from fat to carbohydrate
oxidationisusuallyimpairedinsubjectspronetoobesityand
in subjects with a family history of diabetes [26–29]. Indeed,
there is strong evidence that defects in substrate switching
cluster together with disturbances in mitochondrial content
and/or function and might be a manifestation of an underly-
ing mitochondrial disorder [30]. In this respect, it has been
demonstratedthatinsulin-resistantoﬀspringofpatientswith
T2DM have reduced mitochondrial function, reduced ATP
synthesisandaccumulationoffatinskeletalmuscle,theliver,
and other cells [31].
3.1. Role of White Fat Mitochondria. The major adipose
depots in the body consist of white adipose tissue (WAT).
Mature white adipocytes require large amounts of ATP to
maintain their diverse functions, and during adipogenesis
mitochondrial biogenesis is an important process [20]. One
of the main tasks of adipose tissue is to generate glycerol 3-
phosphate and acetyl-CoA for esteriﬁcation into TGs (lipo-
genesis), processes localized to the mitochondrial matrix as
well as the cytosol, that require an abundant mitochondrial
population [32, 33]. Mitochondria in WAT are also believed
to be important for the regulation of lipolysis, the process
of degrading TG into FFA and glycerol (Figure 2(A)). When
inhibiting the mitochondrial respiratory chain or decreasing
intracellular ATP by the use of mitochondrial uncouplers,
lipolysis is inhibited [34]. Inhibition of the AMP-activated
protein kinase (AMPK), which is an essential molecular sen-
sor regulated by the ATP/AMP level in the cells, will decrease
lipolysis stimulated by agonists of β-adrenoreceptors [35].
The FFAs produced by lipolysis can subsequently be utilized
in the adipocytes as a source of energy, through β-oxidation
in the mitochondria. Thus, mitochondria in white fat cells
are involved in both de novo lipogenesis and lipolysis [36].
Depending on the anatomical position in the body,
adipose tissue shows diﬀerences in metabolic activity due to
diﬀerent mitochondrial density. For example, rat epididymal
(VAT) adipocytes have more mitochondria than inguinal
(SAT) adipocytes [37]. The higher number of mitochondria
per mg tissue in VAT than SAT is also observed in obese
human individuals. Although mitochondrial respiratory ﬂux
per cell and per mitochondrial content was lower in VAT
compared to SAT due to smaller cells, the visceral fat was
bioenergetically more active and responsive to substrates of
the electron transport chain [38]. In general, some studies
show that obesity and T2DM in humans reduce mitochon-
drial number in white adipocytes [39], while others show a
connection between mitochondrial number and lipogenesis,
but not body mass index (BMI) or overall insulin sensitivity
[40]. The link between mitochondrial dysfunction and
T2DMisindicatedbythereducedoxidativephosphorylation
(OXPHOS) capacity in elderly subjects [41], and in obese
subjects, where a reduced FA β-oxidation in several tissues
including adipocytes will increase blood FFA levels and
alter glucose uptake [10, 11]. Nonalcoholic steatohepatitis,
a disease caused by lipid accumulation in the liver, is
associated with mitochondrial dysfunction due to increased
lipid peroxidation, alterations in mitochondrial ultrastruc-
ture, depletion in mtDNA, and low OXPHOS activity.
These patients also commonly display abdominal obesity,
diabetes, and hypertriglyceridemia with insulin resistance
[42]. In rodent genetic or high-fat fed obesity models,
the expression of genes involved in mitochondrial ATP
production, energy uncoupling and other genes important
for mitochondrial function was downregulated compared to
leancontrolanimals[43].Thisindicatesastrongimpairment
of mitochondrial biogenesis during obesity.
3.2. Role of Brown Fat Mitochondria. Although brown
adipose tissue (BAT) is mainly found in newborns, recent
studies have demonstrated its presence in adults [44, 45].
BAT originates from a diﬀerent cellular lineage than WAT
[46], but they share many features. However, mature BAT
contains a higher number of mitochondria and lower
numbers of lipid droplets. During cold temperatures and
activation of the sympathetic nervous system [47], brown
adipocyte lipolysis occurs (Figure 2(B)). Instead of being
released for subsequent oxidation in organs such as liver
and skeletal muscle, the resulting FFAs are oxidized in the
BAT mitochondria and used to generate heat (see review in
[48]). This process involves transport of FFA complexed to
fatty acid binding proteins (FABPs) into the mitochondria
by the carnitine shuttle system, where they are oxidized and
used to generate heat by uncoupling protein 1 (UCP1), a
process called nonshivering thermogenesis. This process is
i m p o r t a n ti nn e w b o r nh u m a n sa n di nr o d e n t s ,b u ta p p e a r s
to be almost lost in adult humans. Although UCP1 is the
hallmark of BAT, increased UCP1 expression and energy
expenditure can also be seen in WAT under some conditions
[49]a n dm a yb ead e s i r a b l ee ﬀect during the treatment of
obesity. The increased expression of the Ucp1 gene in both
BAT and WAT by a fat-speciﬁc aP2 promoter generated mice
partially resistant to age-related obesity, both genetically and
high-fat diet induced [50, 51]. The eﬀect of BAT on obesity
is further discussed below.
4.TranscriptionalRegulation of
LipolysisandLipogenesis
Peroxisome proliferator-activated receptors (PPARs) are
important regulators of fatty acid metabolism. They serve as
lipid sensors since they are activated by metabolic derivates
of fatty acids in the body. There are three PPAR superfamily
members PPARα,P P A R γ,a n dP P A R δ (also called PPARβ)
that act upon ligand activation by controlling networks of
target genes. It exceeds the scope of this paper to describe
their function in detail, but the relevant PPARs will be
mentioned brieﬂy here. For a comprehensive review on the
role of PPARs in metabolic syndrome, see Guri et al. [52].
PPARα is the most important PPAR in the liver and
has many important target genes involved in fatty acid
β-oxidation. During fasting, lipolysis is stimulated whileJournal of Obesity 5
lipogenesis is decreased. The increase in lipolysis provides
FFAs that are used as energy source in other tissues [53].
The subsequent PPARα-regulated metabolism of fatty acids
mainly takes place in the liver, through mitochondrial and
peroxisomal β-oxidation, but the heart, adipose tissue, and
skeletal muscle can also utilize FFA for energy.
The decrease in lipogenesis is on the other hand due
to downregulation of the two main lipogenic transcription
factors, PPARγ and steroyl regulatory element binding
protein 1c (SREBP1c) [54, 55]. Two isoforms of PPARγ exist,
of which PPARγ1i se x p r e s s e di naw i d ev a r i e t yo ft i s s u e s ,
while PPARγ2 is mainly expressed in adipose tissue [56].
PPARγ activation stimulates preadipocyte diﬀerentiation,
promotes the storage of fatty acids in mature adipocytes
[56],andcanactivateGLUT4,facilitatingincreasedfattyacid
synthesis from glucose [57]. SREBP1c is necessary for the
insulin-stimulated increase in fatty acid synthesis [58]. Its
activation has been shown to create ligands for PPARγ [59],
as well as regulate PPARγ expression in cultured adipocytes
[60]. Lipogenesis mainly takes place in the cytosol, but the
activation of PPARγ using rosiglitazone has been shown
to alter both mitochondrial density and morphology in
adipocytes suggesting that PPARγ also controls mitochon-
drial functions [36]. In obese db/db mice, the adiponectin
expression and mitochondrial content of white adipocytes
are reduced, and these eﬀects are reverted by the activation
of PPARγ by rosiglitazone [61]. It is interesting to note
that rosiglitazone can increase expression of mitochondrial
genes/mitochondrial biogenesis in rodent obesity models
[43].
5. Differential Role of Fat Depots
Although the total adipose tissue is important for the
development of insulin resistance, it is believed that some
fat depots are more linked to risk factors for disease than
others. The main adipose depots of interest are found in the
abdomen and can be divided into the SAT and VAT, and
the visceral tissue can again be divided into omental and
mesenteric, the latter being the more deeply buried depot
surrounding the intestine (Figure 1). Some studies have also
included a deep subcutaneous layer(dSAT). The distribution
of SAT and VAT shows person-to-person variations and is
d e p e n d e n to ns e v e r a lf a c t o r ss u c ha sa g e ,n u t r i t i o n ,s e x ,
and the energy homeostasis of the individual adipose tissues
[62]. Both human studies and rodent obesity models will
be discussed below. Although several similarities exist, the
diﬀerences in rodent and human adipose tissues entail
caution when choosing which depots to study and when
extrapolating information between species [63].
5.1. Visceral Fat. Particularly, visceral fat depots, including
omental and mesenteric adipose tissue, represent a risk
factor for the development of CVD and T2DM. Visceral
adipose tissue mass correlates with development of insulin
resistance, while total or subcutaneous tissue mass does not
[62, 64, 65]. It has been thoroughly conﬁrmed that the
adipocytes of visceral fat tissue are more lipolytically active
than subcutaneous adipocytes and thus contribute more to
the plasma free fatty acid levels [62, 66]. This was found in
particular in diabetic obese individuals, where it was linked
to a signiﬁcant upregulation of leptin and downregulation of
adiponectin gene expression in mesenteric VAT compared to
SAT and omental VAT [67].
The metabolic activity of a cell is dependent on its
mitochondrial content, and it has been shown that, in
rats, epididymal (VAT) adipocytes have more mitochondria
than inguinal (SAT) adipocytes [37]. In adipose tissue from
obese individuals undergoing bariatric surgery the relative
OXPHOS activity was found to be higher in omental VAT
than SAT [38]. Individuals with a polymorphism in the
UCP1 promotor reducing UCP1 gene expression are prone
to have a high BMI, in particular due to abdominal obesity
[68].Thus,thelevelofmitochondrialuncouplingandenergy
eﬃciency may have an eﬀect on obesity in WAT as well as
BAT.Thehigherexpressionlevelofbeta-adrenergicreceptors
in VAT could contribute to the higher lipolytic activity [69].
In addition, insulin-stimulated glucose uptake was found to
be higher in VAT compared to SAT [70]. As a result, excess
visceral fat will enhance the level of free fatty acid delivered
to the liver, thus increasing hepatic glucose and very low-
densitylipoproteinparticles(VLDLs)output,andimpairthe
hepatic insulin response.
The expression of PPARγ mRNA is increased in the
adipose tissue of obese subjects [71], and it has been shown
that while there was no diﬀerence in omental VAT and
SAT, PPARγ was signiﬁcantly higher expressed in mesenteric
VAT and remarkably so in obese diabetic subjects [67]. This
supports the involvement of PPARγ in mesenteric adipose
tissue lipolysis. In rats, lipid synthesis is shown to be higher
in internal adipose tissues compared to SAT [72]. A study
comparing the gene expression pattern in rat retroperitoneal
(rVAT), mesenteric VAT (mVAT), and inguinal SAT (iSAT)
showed that the larger cells in rVAT expressed high amounts
of the lipogenic transcription factors Pparγ and Srebp1c
compared to mVAT and iSAT that showed a high expression
of lipogenesis-related genes and a low expression of fatty
acid oxidation-related genes [73]. They also showed that the
genesinvolvedinlipidmetabolismchangedmorerapidlyasa
result of fasting in the internal rVAT depot compared to SAT
[74].
5.2. Subcutaneous Fat. As SAT is less metabolically active
than VAT, it may have better short-term and long-term
storage capacity. Thus, this depot is important to accumulate
TG in periods of excess energy intake and supply the
organism with FFAs in periods of fasting, starvation, or
exercise. Another suggested role of SAT is to be a buﬀer
during intake of dietary lipids, thus protecting other tissues
from lipotoxic eﬀects [75].
In humans, SAT is anatomically divided by a stromal
fascia (fascia superﬁcialis) into superﬁcial (sSAT) and deep
subcutaneous adipose tissue (dSAT), with distinct histo-
logical features. While sSAT has not been linked to risk
for T2DM, the size of dSAT depots is signiﬁcantly linked
to the fasting insulin level and insulin-stimulated glucose6 Journal of Obesity
utilization, as is total fat and VAT [76, 77]. The association
between dSAT and insulin resistance is particularly seen in
male obese patients [77, 78]. When studying the expression
and secretion of hormones and cytokines in lean subjects,
dSAT was found to be more similar to VAT than sSAT
[79]. Interestingly, SAT seem to have an exclusive role in
leptin secretion, since it correlates with plasma leptin levels
(in contrast to plasma insulin levels which correlate with
inter abdominal fat [80]). Rat studies have shown that
Pparγ2 expression is higher in male than in female SAT
[81], indicating a gender-linked variation in this adipose
depot.
5.3. Gluteofemoral Fat. The subcutaneous gluteofemoral fat
tissue is measured by hip or thigh circumference, or leg
adipose tissue mass. Accumulation of fat in this depot
is believed to have a protective role against diabetes and
cardiovasculardisease[82].Indeed,lowamountofthistissue
has been associated with an unfavorable lipid and glucose
proﬁle [83]. Likewise, an increase in gluteofemoral tissue
size has been connected to increase in HDL-cholesterol and
decrease in total- and LDL-cholesterol levels in several stud-
ies [83–85]. Gluteofemoral fat is also positively associated
with adiponectin and leptin serum levels [86]. Tracing of
speciﬁc lipid fraction in blood samples from veins draining
femoral or abdominal fat showed that there was a lower
metabolic ﬂux from femoral fat [87] and that femoral fat had
a preference for uptake of FFA and VLDL-TG compared to
chylomicron-TG, thus accumulating recycled fat rather than
dietary fat.
The gluteofemoral fat tissue may thus provide protection
from ectopic deposition of excess fat. While the abdominal
subcutaneous adipose tissue has a role as buﬀer during
daily fatty acid intake [75], the gluteofemoral fat tissue may
have an important role in TG storage. Since it shows less
metabolic activity and is more lipolytically inert than upper-
bodyadiposedepots,itseemstobeinvolvedinthelong-term
sequestering of fatty acids.
5.4. Intermuscular Fat. Few studies have focused on inter-
muscular adipose tissue (IMAT), and little is known about
its speciﬁc metabolic activities. However, due to its increased
level in T2DM patients, IMAT has been suggested be a
risk factor along with VAT for the development of obesity-
related diseases [88]. The amount of IMAT seems to be
associated with age and lack of activity [89], and increases
the likelihood of metabolic abnormalities in elderly subjects
with normal body weight. In one study, only one third of
men and less than half of women with T2DM were obese,
but in the normal weight subjects, high amounts of IMAT
was associated with higher fasting insulin levels [90]. Also,
IMAT correlates negatively with glucose infusion rate [91],
and fasting glucose and total cholesterol level in Caucasians
[92],indicatingitsinvolvementinthedevelopmentofinsulin
resistance. The amount of IMAT seem to be hereditary since
African-Americans, who are also prone to develop T2DM,
have more of this fat type [93].
5.5. Epicardial Fat. Epicardial adipose tissue (EAT) is the
visceral fat layer located around the heart and is believed to
be important for the buﬀering of the coronary arteries, and
in providing fatty acids as a source of energy for the cardiac
muscle. The release of adiponectin and adrenomedullin
could have a protective eﬀect on the heart during metabolic
or mechanical insults [94]. On the other hand, it has recently
been shown that EAT will locally inﬂuence heart and vascu-
lature through the secretion of pro-inﬂammatory cytokines
and will contribute to coronary atherosclerosis [95–97].
Studies indicate that the amount of EAT can be related to
carotid artery stiﬀness in obese patients with hypertension,
while waist circumference shows no statistically signiﬁcant
link [98]. Age seem to determine the risk associated with
epicardial fat, since there is no relationship between EAT
thickness and insulin resistance and metabolic syndrome in
obese children [99].
A study of patients undergoing coronary artery bypass
surgery showed that the fat layer closest to the heart
expressed 5-fold higher UCP1 mRNA than the more distal
substernal fat, while UCP1 expression was undetectable
in subcutaneous thoracic fat [100]. The UCP1 expression
was inﬂuenced by age and body mass index, but showed
no relationship to epicardial fat volume, waist circum-
ference, metabolic syndrome or T2DM. This, along with
the increased expression of brown adipocyte diﬀerentiation
transcription factors PRDM16 and PGC-1α, indicate that
epicardial fat may have a function similar to brown fat.
This could possibly give an additional protection of the
myocardium and coronary vessels from hypothermia, but its
eﬀect on obesity-linked disease is unknown.
5.6. Gonadal Fat. Gonadal VAT is one of the largest adi-
pose depots in rodents and is found around the testis
of males (epididymal) and around the ovaries of females
(periovarian). This depot is speciﬁcally increased in rodents
fed a cafeteria diet. Gonadal VAT has been shown to
express more of Pparγ and Srebp1c as well as another key
adipogenic transcription factor, CCAAT enhancer-binding
protein alpha (C/EBP-alpha)c o m p a r e dt oS A T[ 101]. Inter-
estingly, PPARγ2 protein was found at a signiﬁcantly higher
level in female than in male rat perigonadal adipose tissue
[81], indicating that sex hormones can aﬀect the regulation
of PPARγ2 in WAT. It is possible that this could contribute to
thegenderdiﬀerencesobservedwithdiﬀerentPPARagonists.
5.7. BAT. The largest region of brown adipose tissue is
found in the upper back region of rodents (interscapular
BAT). In humans, small areas are found in the thorax
region (supraclavicular), and in the chest and abdomen
[44]. There are indications that the nonshivering heat
generation is important for the development of obesity [48].
Mice lacking UCP1 demonstrates increased obesity with
age when fed high-fat diets [102], and selective destruction
of BAT leads to obesity and reduced energy expenditure
and insulin resistance [103]. Interestingly, overnurished rat
pups displayed excess weight gain, reduced thermogenic
capacity, and lower levels of UCP1 as adults [104]. It seemsJournal of Obesity 7
that reduced amount and thermogenic capacity of BAT
may contribute to a life-long predisposition for obesity.
Although adult humans possess only a small percentage of
BAT compared to WAT, the possibility to pharmacologically
increase BAT amount or activity would be a potential
treatment for obesity. Recent studies have demonstrated that
the forced expression of transcription factors PRDM16 and
C/EBP-beta is suﬃcient to generate brown fat cells from
myoblastic precursors [105]. The activation of PPARγ by
diﬀerent agonists has been shown to induce the expression
of brown adipose genes in white adipocytes [106], the
diﬀerentiation of brown adipose progenitor cells [107], and
theproliferationofBATinratsandmonkeys[108].However,
long-term activation of the sympathetic nervous system by
drugs such as ephedrine and BAT proliferation with the
PPARγ agonist the thiazolidinedione darglitazone have been
linked to numerous side eﬀects [108, 109].
6.TargetingMitochondrialFunctionby
BioactiveComponents
6.1. The Eﬀect of Dietary Supplementation with Bioactive
Lipids. Adipose tissue plays a major role in the inﬂamma-
tion, insulin resistance, and dyslipidemia associated with
obesity. It is therefore beneﬁcial to use compounds that
therapeutically target adipose tissue to avoid high-risk
complications of obesity such as T2DM and CVD. Dietary
lipids may inﬂuence the energy balance and are shown to
haveadiﬀerentialeﬀectondiﬀerentfatdepots.Studiesinrats
have shown that ﬁsh oil or n-3 polyunsaturated fatty acids
(n-3 PUFA) intervention reduces epididymal and perirenal
adiposetissuesalthoughthebodyweightstaysconstant[110,
111]. It is believed that ﬁsh oil can aﬀect adipose tissue by
the activation of PPARα and γ, leading to decreased lipolysis,
improved lipid storage capacity in subcutaneous adipose
tissue, as well as anti-inﬂammatory eﬀects possibly due to
inhibitoryactiononNF-κB[112].Ithasbeenshownthatﬁsh
oil at 15% (w/w) level of substitution in a 35% high-fat diet
prevented fat accumulation in C57BL/6 mice, preferentially
in abdominal fat depots [113–115]. This dose of ﬁsh oil
also induced mitochondrial biogenesis in white fat, with a
stronger eﬀect in epididymal than in subcutaneous adipose
tissue [114]. AMPK could be involved in this metabolic
switch that increases adipocyte fatty acid metabolism,
decreaseslipolysis,andupregulatesmitochondrialbiogenesis
[116]. The anti-inﬂammatory eﬀect of n-3 PUFA in mice
has been associated with increased adiponectin secretion
[116, 117], possibly resulting from AMPK activation. This
inductionofadiponectinisprobablymediatedbyPPARγ and
is higher in epididymal fat than in SAT [118].
The artiﬁcially made 3-thia sulphur fatty acid tetrade-
cylthioacetic acid (TTA) has a targeted eﬀect on mitochon-
dria and exhibit high potency compared to ﬁsh oil, both
with regard to increased fatty acid β-oxidation and anti-
inﬂammatory eﬀects [119]. TTA thus shows great promise
in the treatment of metabolic syndrome (Figure 3). It is
a 16-carbon saturated fatty acid where a sulfur atom is
inserted between the second and the third carbon in the
β-position, thus making it unavailable for fatty acid β-
oxidation. The mechanism of action of TTA is based mainly
on the activation of PPARs, which induce mitochondrial
biogenesis and enhance fatty acid oxidation in the liver
[119–121]. This has been suggested to remodel WAT tissues
due to drainage of fatty acids towards the liver. TTA was
shown to speciﬁcally reduce epididymal fat in young obese
Zucker (fa-fa) rats and epididymal and retroperitoneal fat
in male Wistar rats fed a high-fat diet for 3 weeks [122].
To further study the eﬀect of TTA-induced adipose tissue
remodelling, Wistar rats were fed a high-fat lard diet (40%
energy from fat) for 7 weeks, and the distribution of fat
was studied by magnetic resonance imaging (MRI). The
adipose tissue mass was signiﬁcantly reduced in the TTA-
fed rats, particularly in the perirenal and epididymal depots
[123]. Interestingly, while most of the genes involved in
lipolysis, fatty acid β-oxidation, mitochondrial biosynthesis,
and immune response were unchanged by TTA in all studied
adipose tissues, Ucp1 was highly increased at the mRNA
level in epididymal and mesenteric depots [123]. Also, a de
novo production of Ucp3 in the liver was detected both at
the mRNA and protein level along with high induction of
genes involved in β-oxidation [123]. The possible increased
energy expenditure due to uncoupling of mitochondria
combined with the enhanced hepatic fatty acid β-oxidation
supports the hypothesis of hepatic lipid drainage. As a
result, TTA treatment will channel TGs to the liver for β-
oxidation and facilitate adipose tissue lipolysis. The higher
metabolic activity of the VAT tissues could explain the
speciﬁc reduction of these risk-linked depots, perhaps also
inﬂuenced by their increase in BAT-like features (Figure 2).
Although the eﬀect of TTA is mostly due to activation of
hepatic mitochondrial genes, activation of some adipose
genes involved in β-oxidation was observed. The lipogenic
genes acetyl-CoA carboxylase alpha (Acaca) and fatty acid
synthase (Fasn) were induced by TTA in perirenal and
epididymal VAT [123]. In a directly comparable long-term
rat study, the 3-n PUFA eicosapentaenoic acid (EPA) was
found to increase Acaca and Fasn in VAT while Cpt2
mRNA-level was increased in mesenteric VAT, indicating an
increase in genes involved in fatty acid degradation also with
marine oils [124]. Ucp1 was on the other hand increased
only by TTA. Similar results have been found in human
adipocytes (not published results). TTA and EPA were able
to signiﬁcantly increase the gene expression of AMPK, CPT2,
UCP1, and acyl-coA oxidase 1 (ACOX1), but TTA induced
ah i g h e rl e v e lo fAMPK and UCP1.I m p o r t a n t l y ,A M P K
is believed to function as a metabolic switch resulting
in upregulation of FA oxidation in parallel with reduced
maloyl-CoA level and downregulated lipogenesis and TG
biosynthesis.
The mitochondrial gene pyruvate kinase (Pklr)w a s
upregulated by TTA speciﬁcally in perirenal VAT [123],
indicating mitochondrial biogenesis in this fat depot. This is
important as the generation of new mitochondria is severely
compromised in several obesity-models [36, 43]. In accor-
dance, a coactivator central for mitochondrial biogenesis,
PPAR coactivator 1α (Pgc-1α) was reduced in a rodent
obesity model [125] and in morbidly obese humans [126].8 Journal of Obesity
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Figure 3: (A) During obesity, the adipocytes will have reduced lipid storage capacity, leading to increased lipolysis and release of free fatty
acids (FFAs), inﬂammatory agents, and disturbed adipokine release. The FFAs will be repackaged to triglycerides (TGs) in the liver where
they are released as very low-density lipoprotein particles (VLDL). Together this has secondary eﬀects on organs such as skeletal muscle and
pancreas, as well as liver, and can result in hyperlipidemia, tissue lipid deposition, mitochondrial malfunction, insulin resistance, increased
insulin production, and pancreatic β-cell disruption. (B) The eﬀect of tetradecylthioacetic acid-(TTA-) treatment on metabolic syndrome.
In the liver, TTA treatment will increase the degradation of FFA, by the induction of both mitochondrial and peroxisomal genes involved in
β-oxidation. The excess FFA released from adipose tissue during metabolic syndrome (hyperlipidemia) is drained from the blood, thereby
reducing TG, cholesterol, and FFA levels. In addition the TTA-induced increase in uncoupling protein 3 (UCP3) could increase energy
expenditure, as well as function as a protection from the excess ROS production observed with obesity and high levels of FA degradation.
The eﬀect of TTA on liver is probably due to PPARα-mediated mechanisms, while the eﬀect on adipose tissue may arrive from PPARγ as
well as PPARα activation. In adipose tissue, the main eﬀect of TTA is an increase in the brown adipose tissue marker Ucp1 in visceral adipose
tissue (VAT) indicating higher energy expenditure and heat production. The higher metabolic activity of VAT compared to SAT will cause
it to be the major source of FFA during increased hepatic β-oxidation. Together, this may explain the speciﬁc reduction of these risk-linked
adipose depots with TTA-treatment.Journal of Obesity 9
Although TTA reduces dyslipidemia in diabetic patients
[121], a direct eﬀect on glucose metabolism and insulin
sensitivity is more disputed [121, 123, 127]. A reduced
amount of risk-related adipose tissue in obese individuals
would however be important to reduce the likelihood of
developing disease. The eﬃcient reduction of plasma FFA
and TG by TTA, seen in both human and animal studies
[128],mayalsopreventectopiclipiddepositionandlipotoxic
eﬀects.
TTA induces mitochondrial biogenesis in liver, but the
eﬀect on mitochondrial respiration has not been fully
elucidated. Although the number of mitochondria increases
in the liver during TTA-treatment, the hepatocytes are
enlarged, and the respiration per mg tissue stays con-
stant (not published results). Little work has been done
to measure oxygen consumption/OXPHOS in adipose tis-
sue, probably due to the diﬃculties caused by a low
mitochondrial density in adipocytes compared to skeletal
muscle [129]. Some studies have successfully determined
mitochondrial OXPHOS in cells or organelles isolated from
both brown and white adipose tissues [130], and VAT
and SAT have been compared using similar techniques
[38]. Information on mitochondrial OXPHOS activity will
be of importance when testing for improved adipose tis-
sue function during treatment with mitochondrial-targeted
compounds.
6.2.RegulationofGeneExpressionintheTreatmentofObesity-
Related Diseases. PPAR is the target of many agents that
restore insulin sensitivity. However, they do not necessarily
decrease adipose tissue size. Thiazolidinediones (TZDs),
such as pioglitazone and rosiglitazone, activate PPARγ
and are associated with increased body weight due to
the ability to stimulate preadipocyte diﬀerentiation [131,
132]. In particular the retroperitoneal VAT [133, 134]a n d
intermuscular fat inﬁltration was increased by TZDs [134].
Studies show that the activation of PPARα by fenoﬁbrates or
oleoyletanolamide reduces adiposity and increases lipolysis
[132], while a pan-PPAR ligand, LM 4156, had no eﬀect on
adipose tissue size [134]. Another study in accordance with
this showed that a PPARα agonist reduced feed intake and
body weight gain but had less eﬀect on glucose intolerance
(GI), a PPARγ agonist improved GI and adiponectin release
but enhanced feed intake and body weight gain, while an
agent with dual PPAR-activation demonstrated a combined,
more beneﬁcial eﬀect [135]. TTA activates both PPARα
and γ, the former with higher eﬃciency [136–138], and
this may partly explain the eﬀect on lipid degradation in
the liver, as well as the reduced weight gain and hepatic
induction of UCP3 primarily associated with PPARα acti-
vation [132, 139]. However, we have shown the existence
of PPAR dependent and independent induction of UCP2
by TTA [140]. Therefore, mechanisms not involving PPAR-
activation may also be important for the eﬀects seen with
TTA.
6.3. ROS Generation and TTA as an Antioxidant. There
is mounting evidence that the increased release of H2O2,
mainly originating from mitochondria, may be an important
step in the development of insulin resistance in diﬀerent
tissues during high-fat intake [15, 16]. Mitochondrial dam-
age is linked to insulin resistance and could be a secondary
eﬀect of the increase in ROS [141] .An u m b e ro fs t u d i e sh a v e
shown that treatment with antioxidants will both improve
oxidative stress and restore insulin sensitivity [141–143].
While antioxidants studied so far have had little eﬀect on
human atherogenesis, it could be worthwhile to investigate
mitochondrial-targeted antioxidants in the treatment of
CVD [5].
TTA mainly aﬀects mitochondrial functions and is a
very potent antioxidant [144, 145] and anti-inﬂammatory
agent [120, 146], both of which may be important for its
reduction of dyslipedemia in diabetic patients [121]. TTA
inhibits the lipoprotein oxidation in rats, indicating that its
eﬀects as an antioxidant may inﬂuence the development of
atherosclerosis [145]. It also reduces the stenosis develop-
ment after balloon angioplasty injury of rabbit iliac arteries
[147]. Recently we have shown downregulated expression
of PPAR target genes and reduced mitochondrial fatty acid
oxidation in the liver of mice transgenic for hTNFα [148].
TTA enhanced the hepatic fatty acid oxidation in these
animals(inpreparation).Moreover,TTAreducedthehepatic
gene expression of TNFα and visfatin [123].
7. Conclusions
The diﬀerent adipose depots have speciﬁc roles based on
their level of lipolysis and rate of TG storage. It is becoming
clear that while abdominal visceral adipose tissue increases
the risk of obesity-related disease, subcutaneous adipose tis-
sue, especially located to the lower-body parts, protects from
lipotoxic eﬀects through short-term and long-term storage
of TGs. In rodent studies, intake of bioactive lipids gives
speciﬁc reduction of risk-related adipose tissues, and this
targeted eﬀect may be due to the higher metabolic activity
of these depots. Treatments that increase energy expenditure
through “mild uncoupling” of mitochondria and fatty acid
β-oxidation show great promise in the treatment of obesity.
The artiﬁcial fatty acid TTA is an inducer of these processes.
Enhanced expression of uncoupling proteins together with
an induction of hepatic β-oxidation suggests that TTA may
increase energy consumption via increased uncoupling in
liver and/or WAT. In addition its activity as an antioxidant
and anti-inﬂammatory agent will have a direct positive
eﬀect on the diseases linked to obesity, such as T2DM and
CVD.
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